FDA approves self-collection HPV tests for cervical cancer screening to improve accessibility.

The FDA has approved self-collection HPV tests for cervical cancer screening, allowing patients to gather their own vaginal samples in healthcare settings. These kits are now being shipped to doctors' offices, aiming to enhance screening accessibility for women, especially those who are under-screened. Approximately 30% of American women are not screened, with two-thirds of cervical cancer cases arising from this group. Regular screening is recommended every three to five years for specific age groups.